|
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
|
Ongoing
|
Acalabrutinib
|
3
|
D8221C00001
|
King Fahad Specialist Hospital (Dammam)
|
|
"A Phase III Double-blind Randomised Study Assessing the Efficacy andSafety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Histologically Confirmed, Locally Advanced(Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)"
|
Ongoing
|
Capivasertib
|
3
|
D3614C00001
|
King Fahad Specialist Hospital (Dammam), King Abdullah Medical City (Makkah), Specialized Medical Center (Riyadh)
|
|
AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY
|
Terminated
|
Risdiplam
|
2
|
BN40703
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
|
Ongoing
|
Sorafenib (Nexavar)
|
3
|
RTOG 1112
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
|
Ongoing
|
DOCETAXEL, Paclitaxel, TAMOXIFEN and Letrozole
|
3
|
S1007
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
|
Ongoing
|
Ozanimod HCl
|
3
|
RPC01-3203
|
King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh)
|
|
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
|
Ongoing
|
CISPLATIN (CISPLATYL )
|
2
|
NRG-HN002
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Study of Aflibercept in Uveitic Macular EDema (SAUD study)
|
Rejected
|
Aflibercept
|
3
|
18176/
|
King Khaled Eye Specialist Hospital (Riyadh)
|
|
A Phase Ib study to determine the safety and immunogenicity of the candidate Middle East Res-piratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers
|
Ongoing
|
vaccine ChAdOx1 MERS
|
1
|
CT18/004/R
|
King Abdulaziz Medical City NG (Riyadh)
|
|
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia
|
Rejected
|
Dasatinib
|
2
|
LPI-JOR-LEB-KSA-TUN-
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
